Palobiofarma announces the completion the Phase II clinical trial with its investigational therapy PBF-680 in chronic obstructive pulmonary disease (COPD) patients

by Palobiofarma

7 days ago
PBF-680, chronic obstructive pulmonary disease (COPD), eosinophils

Palobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe COPD patients.

PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received “Orphan Drug Designation” by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA)

by Palobiofarma

2 months ago
Prader-Willi Syndrome, PBF-99

The Orphan Drug Designation indicates the acknowledgement by the Regulatory Authorities of USA and the EU that PBF-999 have the potential to address the specific needs of individuals suffering from Pr...

Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team

by Palobiofarma

2 months ago
Palobiofarma, Sodena, Inveready

The investment will be used to complete three phase II clinical trials in which the efficacy of its most advanced products is being studied, namely PBF-680 in patients with chronic obstructive pulmona...

Palobiofarma Receives Rare Pediatric Disease Designation from the U.S. FDA for PBF-999 for the Treatment of Prader-Willi Syndrome

by Palobiofarma

6 months ago
Palobiofarma, Rare Pediatric Disease (RPD) Designation, FDA, Prader-Willi Syndrome

Palobiofarma has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s phosphodiesterase 10 (PDE-10) inhibitor, PBF-999, f...

Palobiofarma announces the enrolment of the first three patients in the clinical study investigating the effects of its novel compound PBF-999 for the treatment of Prader-Willi Syndrome

by Palobiofarma

12 months ago
Prader-Willi Syndrome (PWS, PBF-999

Palobiofarma S.L., a biopharmaceutical company dedicated to the discovery and development of innovative drugs, has enrolled the first three patients in a clinical study to investigate the potential of...

Palobiofarma announces a collaboration with the Foundation for Prader Willi Research (FPWR) for the development of PBF-999 as a novel treatment for the Prader Willi Research syndrome

by Palobiofarma

12 months ago
Prader Willi Research syndrome, PBF-999, hyperphagia

FPWR’s philanthropic investment will be used to partially fund Palobiofarma’s ongoing Phase 2 clinical trial to develop PBF-999 for the treatment of Prader Willi syndrome (PWS).

Medibiofarma cierra nueva ronda de financiación por valor de 1,

by Palobiofarma

2 years ago
Medibiofarma

Medibiofarma ha cerrado una ronda de financiación de 1,2 millones de euros, con el apoyo financiero de su equipo promotor y otros socios de contrastada experiencia en el ámbito de la salud y la tecn...

Palobiofarma announces that it has been included among the 99 innovative companies in the European Innovation Council Accelerator

by Palobiofarma

2 years ago
Palobiofarma, European Innovation Council Accelerator

Palobiofarma has received the approval of the European project that finances Phase II of the PBF-680 product in COPD. Additionally, it offers the possibility of partial financing of Phase III of PBF-6...

Palobiofarma announces positive results in the Phase IIa clinical trial evaluating it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitis

by Palobiofarma

2 years ago
Ulcerative Colitis, clinical trial

The Phase II trial studied the safety, tolerability, and preliminary efficacy of PBF-677 in patients with mild to moderate Ulcerative Colitis in flair condition on top of the standard of care Mesalazi...

Positive clinical results of Palobiofarma´s adenosine A1 antagonist PBF-680 presented at the European Respiratory Society meeting

by Palobiofarma

4 years ago
oral asthma therapy, allergen, adenosine

The results of an allergen POC trial in asthmatics will summarized by Dr. David Ramos, principal investigator of the PBF-680 clinical program, in an oral presentation titled:

Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients

by Palobiofarma

4 years ago
clinical trial, drug, asthmatics

The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo.

Palobiofarma joins the fight against the Covid-19 pandemia

by Palobiofarma

4 years ago
research, CDTI, covid-19

The company announced the initiation a of a drug discovery program towards the identification of novel oral drugs specifically designed to treat infections caused by Corona viruses.